Primary endpoint: 6-minute walk<\/strong> distance (6MWD)<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nIn STELLAR, a 24-week study of adults with PAH on background therapy:<\/strong><\/h4><\/div>\n\n\n\nWINREVAIR delivered a significant step forward for patients<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/div>![\"\"\/](\"https:\/\/www.merckconnect.com\/winrevair\/wp-content\/uploads\/sites\/112\/2025\/07\/1-1.png\")
<\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\nActor Portrayal<\/p>\n<\/div>\n\n\n\n
\nPatients taking WINREVAIR walked<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n41 meters more<\/mark><\/strong>\u1d43<\/mark> <\/strong>(95% CI: 28: 54; P<\/em><0.001)<\/span><\/span><\/p><\/div><\/div>\n\n\n\nin 6 minutes at 24 weeks than patients on background therapy alone<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nPlacebo-adjusted median increase from baseline in 6MWD<\/p><\/div><\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nIn a 24-week clinical study of adults with PAH (WHO Group 1, FC II or III) on stable background therapy, patients (N=323) were randomized 1:1 to WINREVAIR (n=163) or placebo (n=160) administered by subcutaneous injection once every 3 weeks.1<\/sup><\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\nChange from baseline in 6MWD at week 24 in subgroups<\/strong>a,b<\/sup><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n![\"Results](\"https:\/\/www.merckconnect.com\/winrevair\/wp-content\/uploads\/sites\/112\/2025\/12\/WIN-desk.png?w=1023\")
![\"Results](\"https:\/\/www.merckconnect.com\/winrevair\/wp-content\/uploads\/sites\/112\/2025\/12\/WIN-MOB.png\" "\\"\\"")
<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\n\n![\"\"\/](\"https:\/\/www.merckconnect.com\/winrevair\/wp-content\/uploads\/sites\/112\/2025\/07\/890_updated.png\")
<\/picture><\/figure><\/div>\n\nPositive improvement trends were observed in prespecified subgroups, including double and triple therapy, and WHO FC II and III\u2028<\/mark><\/strong><\/mark><\/strong><\/p><\/div><\/div>\n\n\nThese subgroup data were consistent with the primary endpoint<\/mark><\/strong><\/p><\/div><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\u1d43Hodges-Lehmann location shift from placebo estimate (median of all paired differences).\u2028<\/p>\n\n\n\n
\u1d47Change from baseline in 6MWD at week 24 for subjects who died was imputed to -2000 meters to receive the worst rank. Change from baseline in 6MWD at week 24 for subjects who had missing data due to a non-fatal clinical worsening event was imputed to -1,000 meters to receive the next-worst rank.\u2028<\/p>\n\n\n\n
CHD = congenital heart disease; CI = confidence interval; CTD = connective tissue diseases; PVR = pulmonary vascular resistance; s\/p = systemic-to-pulmonary.<\/p>\n\n\n\n
<\/div>\n\n\n\nReference:<\/strong>
1.<\/strong> Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med.<\/em> 2023;388(16):1478-1490.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\n\nReport exposure during pregnancy or lactation to the Merck Sharp & Dohme<\/span>, LLC Adverse Event reporting line at 1-877-888-4231<\/span><\/strong><\/h6><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nNavigate to:<\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\n
In STELLAR, a 24-week study of adults with PAH on background therapy:<\/strong><\/h4><\/div>\n\n\n\nWINREVAIR delivered a significant step forward for patients<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/div><\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\nActor Portrayal<\/p>\n<\/div>\n\n\n\n
\nPatients taking WINREVAIR walked<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n41 meters more<\/mark><\/strong>\u1d43<\/mark> <\/strong>(95% CI: 28: 54; P<\/em><0.001)<\/span><\/span><\/p><\/div><\/div>\n\n\n\nin 6 minutes at 24 weeks than patients on background therapy alone<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nPlacebo-adjusted median increase from baseline in 6MWD<\/p><\/div><\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nIn a 24-week clinical study of adults with PAH (WHO Group 1, FC II or III) on stable background therapy, patients (N=323) were randomized 1:1 to WINREVAIR (n=163) or placebo (n=160) administered by subcutaneous injection once every 3 weeks.1<\/sup><\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\nChange from baseline in 6MWD at week 24 in subgroups<\/strong>a,b<\/sup><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/picture><\/figure><\/div>\n\nPositive improvement trends were observed in prespecified subgroups, including double and triple therapy, and WHO FC II and III\u2028<\/mark><\/strong><\/mark><\/strong><\/p><\/div><\/div>\n\n\nThese subgroup data were consistent with the primary endpoint<\/mark><\/strong><\/p><\/div><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\u1d43Hodges-Lehmann location shift from placebo estimate (median of all paired differences).\u2028<\/p>\n\n\n\n
\u1d47Change from baseline in 6MWD at week 24 for subjects who died was imputed to -2000 meters to receive the worst rank. Change from baseline in 6MWD at week 24 for subjects who had missing data due to a non-fatal clinical worsening event was imputed to -1,000 meters to receive the next-worst rank.\u2028<\/p>\n\n\n\n
CHD = congenital heart disease; CI = confidence interval; CTD = connective tissue diseases; PVR = pulmonary vascular resistance; s\/p = systemic-to-pulmonary.<\/p>\n\n\n\n
<\/div>\n\n\n\nReference:<\/strong>
1.<\/strong> Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med.<\/em> 2023;388(16):1478-1490.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\n\nReport exposure during pregnancy or lactation to the Merck Sharp & Dohme<\/span>, LLC Adverse Event reporting line at 1-877-888-4231<\/span><\/strong><\/h6><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nNavigate to:<\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\n
WINREVAIR delivered a significant step forward for patients<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/div><\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\nActor Portrayal<\/p>\n<\/div>\n\n\n\n
\nPatients taking WINREVAIR walked<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n41 meters more<\/mark><\/strong>\u1d43<\/mark> <\/strong>(95% CI: 28: 54; P<\/em><0.001)<\/span><\/span><\/p><\/div><\/div>\n\n\n\nin 6 minutes at 24 weeks than patients on background therapy alone<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nPlacebo-adjusted median increase from baseline in 6MWD<\/p><\/div><\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nIn a 24-week clinical study of adults with PAH (WHO Group 1, FC II or III) on stable background therapy, patients (N=323) were randomized 1:1 to WINREVAIR (n=163) or placebo (n=160) administered by subcutaneous injection once every 3 weeks.1<\/sup><\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\nChange from baseline in 6MWD at week 24 in subgroups<\/strong>a,b<\/sup><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/picture><\/figure><\/div>\n\nPositive improvement trends were observed in prespecified subgroups, including double and triple therapy, and WHO FC II and III\u2028<\/mark><\/strong><\/mark><\/strong><\/p><\/div><\/div>\n\n\nThese subgroup data were consistent with the primary endpoint<\/mark><\/strong><\/p><\/div><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\u1d43Hodges-Lehmann location shift from placebo estimate (median of all paired differences).\u2028<\/p>\n\n\n\n
\u1d47Change from baseline in 6MWD at week 24 for subjects who died was imputed to -2000 meters to receive the worst rank. Change from baseline in 6MWD at week 24 for subjects who had missing data due to a non-fatal clinical worsening event was imputed to -1,000 meters to receive the next-worst rank.\u2028<\/p>\n\n\n\n
CHD = congenital heart disease; CI = confidence interval; CTD = connective tissue diseases; PVR = pulmonary vascular resistance; s\/p = systemic-to-pulmonary.<\/p>\n\n\n\n
<\/div>\n\n\n\nReference:<\/strong>
1.<\/strong> Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med.<\/em> 2023;388(16):1478-1490.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\n\nReport exposure during pregnancy or lactation to the Merck Sharp & Dohme<\/span>, LLC Adverse Event reporting line at 1-877-888-4231<\/span><\/strong><\/h6><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nNavigate to:<\/strong><\/h4><\/div>\n\n\n\n<\/div>\n\n\n\n
<\/picture><\/p><\/figcaption><\/figure><\/div>\n\n\n\n
Actor Portrayal<\/p>\n<\/div>\n\n\n\n
Patients taking WINREVAIR walked<\/p><\/div><\/div>\n\n\n\n
41 meters more<\/mark><\/strong>\u1d43<\/mark> <\/strong>(95% CI: 28: 54; P<\/em><0.001)<\/span><\/span><\/p><\/div><\/div>\n\n\n\n in 6 minutes at 24 weeks than patients on background therapy alone<\/p><\/div><\/div>\n\n\n\n Placebo-adjusted median increase from baseline in 6MWD<\/p><\/div><\/div>\n\n\n\n Positive improvement trends were observed in prespecified subgroups, including double and triple therapy, and WHO FC II and III\u2028<\/mark><\/strong><\/mark><\/strong><\/p><\/div><\/div>\n\n\n These subgroup data were consistent with the primary endpoint<\/mark><\/strong><\/p><\/div><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n \u1d43Hodges-Lehmann location shift from placebo estimate (median of all paired differences).\u2028<\/p>\n\n\n\n \u1d47Change from baseline in 6MWD at week 24 for subjects who died was imputed to -2000 meters to receive the worst rank. Change from baseline in 6MWD at week 24 for subjects who had missing data due to a non-fatal clinical worsening event was imputed to -1,000 meters to receive the next-worst rank.\u2028<\/p>\n\n\n\n CHD = congenital heart disease; CI = confidence interval; CTD = connective tissue diseases; PVR = pulmonary vascular resistance; s\/p = systemic-to-pulmonary.<\/p>\n\n\n\n Reference:<\/strong>In a 24-week clinical study of adults with PAH (WHO Group 1, FC II or III) on stable background therapy, patients (N=323) were randomized 1:1 to WINREVAIR (n=163) or placebo (n=160) administered by subcutaneous injection once every 3 weeks.1<\/sup><\/strong><\/h4><\/div>\n\n\n\n
Change from baseline in 6MWD at week 24 in subgroups<\/strong>a,b<\/sup><\/h2><\/div>\n\n\n\n
<\/figure><\/div>\n\n\n\n<\/picture><\/figure><\/div>
1.<\/strong> Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med.<\/em> 2023;388(16):1478-1490.<\/p><\/div><\/div>\n\n\n\nReport exposure during pregnancy or lactation to the Merck Sharp & Dohme<\/span>, LLC Adverse Event reporting line at 1-877-888-4231<\/span><\/strong><\/h6><\/div>\n<\/div>\n<\/div>\n\n\n\n
Navigate to:<\/strong><\/h4><\/div>\n\n\n\n